



SHAREHOLDER NEWSLETTER

Autumn, 2015



From the CEO

TruScreen has opened the door on a NZ\$1billion per annum market with the recent granting of China Food and Drug Administration (CFDA) approval to market TruScreen in China.

This watershed achievement is just one of the many milestones attained by TruScreen in the past 12 months, including listing on the NZ Stock Exchange's NZAX Market.

Most notably, TruScreen has achieved (subject to audit) revenues in excess of NZ\$1.9 million for the financial year to March 31, 2015 - in line with the forecast in our disclosure document.

In addition, TruScreen has established distribution partnerships in key target markets; conducted a miniaturisation and mobilisation program to develop a next generation TruScreen device; and continued to develop upgraded algorithms to further improve TruScreen's ability to identify patients at risk of developing cervical cancer.

TruScreen has also engaged the services of a panel of experts with extremely high credentials as Medical Advisory and R&D Committees, whose experience has been critical to our development.

This newsletter is an opportunity for us to update you, our shareholders and supporters, on our story. Thank you for your continued support.

Martin Dillon CEO

CHINA - THE NEXT BIG THING

With a market potential of more than NZ\$1billion per annum China is a standout market for TruScreen.

The granting of CFDA approval has been the culmination of more than a year of rigorous testing in clinical and in-field trials conducted by TruScreen and our partners in China and examined by the CFDA's Centre for Medical Device Evaluation. Their decision is not only a validation of TruScreen's technical excellence and performance levels, but also its particular relevance as a primary screening tool in the largest of the low health resource economies in the world – which are our target markets.

TruScreen is ready-to-market in China.

While the CFDA's evaluation of TruScreen was being conducted our team, and our distributors have established a ready-to-market capability so that we can, without delay, take full commercial advantage of this watershed achievement.

Inventory has been built up ready for immediate installation, training has been conducted, logistical pathways established, key influencing hospital relationships cemented and the planning for the initial roll out of major programs completed.



380 million
women of screening age

Potential Market
NZ\$1billion p.a.

Revenue Forecast Achieved

TruScreen expects to report a revenue result exceeding \$1.9 million for the year ended 31 March, 2015 (subject to audit).

TruScreen was listed on the NZAX on 12 November, 2014

Primary Exchange: NZAX

Ticker Code: TRU

Shares on Issue: 144,446,666

Revenue FY March 2015: NZD \$1.9m


Directors: Robert Hunter, Sean Joyce, Chris Horn, Tim Preston

Advisory Boards: Prof N Hacker, Prof R W Jones, Dr John Blakemore PhD, Dr M Campion, Dr E Bardon

Website: www.truscreen.com

Share Registry: Link Market Services.

HISTORIC SALES BY REGION




Who We Are

TruScreen Limited is a New Zealand listed company which owns a unique real time cervical cancer screening system.

The Global Cancer Screening market is estimated to be worth more than NZD NZ\$4billion per annum. Each year there are over 500,000 new cases and 250,000 deaths, with close to 90% of those deaths occurring in developing countries. These low health resource countries are TruScreen's target markets.

TruScreen uses electro-optical technologies for the identification of pre-cancerous and cancerous tissue, with a current focus on screening for cervical cancer. The technology utilises a digital wand which is touched on the surface of the cervix to measure electrical and optical signals from the surrounding tissue to identify precancerous changes.

HOW TRUSCREEN WORKS



NEXT GEN DEVICE DUE IN Q3


With TruScreen receiving positive feedback from specialists and patients around the globe, our team has been busy working on the next generation device, due for production and release in Q3 of 2015.

CEO Martin Dillon says the new device is the result of an 18 month 'miniaturisation and mobilisation' program. "The mobilisation part means the new device is wireless," he explains. "The handpiece is not physically connected to the cradle, and it is wireless in its communication, so it will talk to any paired PC, laptop or smart device."

Smaller and easier to use, the internal workings have at the same time been expanded.

"It will have significantly increased processing capacity, and significantly improved memory storage as well," Dillon explains. "In layman's terms these improvements in processing power have taken a house and turned it into a skyscraper."

The company is also looking ahead to further potential applications of the device to screen other human cancers.



TruScreen Approved by FDA Thailand

The Thai Food and Drug Administration's (FDA Thailand) approval to market TruScreen in Thailand is of key strategic significance for broader sales in the ASEAN region.

The total potential ASEAN cervical cancer screening market is estimated at NZ\$430million per annum. With a potential market for cervical cancer screening estimated at NZ\$50million per

annum, Thailand is a key strategic location and augments our existing ASEAN distribution channels in the Philippines, Vietnam and Indonesia. TruScreen will capitalise on this latest approval to immediately commence marketing in the ASEAN region.

TruScreen has distribution contracts in 11 regions, including China, Latin America, South East Asia, Central Asia, Russia the Middle East and Eastern Europe.